Combinations of TLR ligands: A promising approach in cancer immunotherapy

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Stier, Saskia ^a   Maletzki, Claudia ^a   Klier, Ulrike ^a   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLE DERIVATIVE; LIGAND; PACLITAXEL; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; TOLL LIKE RECEPTOR;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMIDAZOLES; IMMUNOMODULATION; IMMUNOTHERAPY; LIGANDS; LYMPHOCYTES; MICE; NEOPLASMS; PACLITAXEL; POLY I-C; TOLL-LIKE RECEPTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893727534     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/271246     Document Type: Article

References (45)

1. Chen G. Y., Nuñez G., Sterile inflammation: sensing and reacting to damage. Nature Reviews Immunology 2010 10 826 837
2. Iwasaki A., Medzhitov R., Toll-like receptor control of the adaptive immune responses. Nature Immunology 2004 5 10 987 995 2-s2.0-5444262511 10.1038/ni1112 (Pubitemid 41057715)
3. Chen L., Xu Y. Y., Zhou J. M., Wu Y. Y., E Q Y. Y., Zhu Y. Y., TLR3 dsRNA agonist inhibits growth and invasion of HepG2. 2. 15 HCC cells. Oncology Reports 2012 28 1 200 206
4. Schön M. P., Schön M., TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008 27 2 190 199 2-s2.0-37848999304 10.1038/sj.onc.1210913
5. Tomai M. A., Miller R. L., Lipson K. E., Kieper W. C., Zarraga I. E., Vasilakos J. P., Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Review of Vaccines 2007 6 5 835 847 2-s2.0-35348990231 10.1586/14760584.6.5.835 (Pubitemid 47607857)
6. So E. Y., Ouchi T., The application of toll like receptors for cancer therapy. International Journal of Biological Sciences 2010 6 7 675 681 2-s2.0-78650494568
7. Kundu S. D., Lee C., Billips B. K., Habermacher G. M., Zhang Q., Liu V., Wong L. Y., Klumpp D. J., Thumbikat P., The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. Prostate 2008 68 2 223 229 2-s2.0-38749139248 10.1002/pros.20710 (Pubitemid 351186234)
8. Schmaußer B., Andrulis M., Endrich S., Müller-Hermelink H., Eck M., Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. International Journal of Medical Microbiology 2005 295 3 179 185 2-s2.0-20144373185 10.1016/j.ijmm.2005. 02.009 (Pubitemid 40776102)
9. Tang X., Zhu Y., Wei B., Wang H., Expression and functional research of TLR4 in human colon carcinoma. American Journal of the Medical Sciences 2010 339 4 319 326 2-s2.0-77950930729 10.1097/MAJ.0b013e3181cef1b7
10. Zaks-Zilberman M., Zaks T. Z., Vogel S. N., Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 2001 15 3 156 165 2-s2.0-0035822818 10.1006/cyto.2001.0935 (Pubitemid 34587497)
11. Song E., Kang M., Kim Y., Kim S., Lee S., Kim C., Kim D., Park J., Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. International Journal of Molecular Medicine 2011 28 1 115 119 2-s2.0-79955872080 10.3892/ijmm.2011.656
12. Salaun B., Coste I., Rissoan M., Lebecque S. J., Renno T., TLR3 can directly trigger apoptosis in human cancer cells. Journal of Immunology 2006 176 8 4894 4901 2-s2.0-33645755382
13. Ahn M. Y., Kwon S. M., Cheong H. H., Park J. H., Lee J., Min S. K., Ahn S. G., Yoon J. H., Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. Journal of Oral Pathology and Medicine 2012 41 540 546
14. Paone A., Starace D., Galli R., Padula F., De Cesaris P., Filippini A., Ziparo E., Riccioli A., Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC- α -dependent mechanism. Carcinogenesis 2008 29 7 1334 1342 2-s2.0-49349103910 10.1093/carcin/bgn149
15. Maletzki C., Klier U., Obst W., Kreikemeyer B., Linnebacher M., Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin. Clinical and Developmental Immunology 2012 2012 15 230625 10.1155/2012/230625
16. Maletzki C., Gock M., Klier U., Klar E., Linnebacher M., Bacteriolytic therapy of experimental pancreatic carcinoma. World Journal of Gastroenterology 2010 16 28 3546 3552 2-s2.0-77955109388 10.3748/wjg.v16.i28.3546
17. Patyar S., Joshi R., Byrav D. S. P., Prakash A., Medhi B., Das B. K., Bacteria in cancer therapy: a novel experimental strategy. Journal of Biomedical Science 2010 17 1, article 21 2-s2.0-77950940044 10.1186/1423-0127-17-21
18. Maletzki C., Linnebacher M., Kreikemeyer B., Emmrich J., Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 2008 57 4 483 491 2-s2.0-41149145055 10.1136/gut.2007.125419 (Pubitemid 351442532)
19. Linnebacher M., Maletzki C., Emmrich J., Kreikemeyer B., Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. Journal of Immunotherapy 2008 31 8 704 713 2-s2.0-59849119193 10.1097/CJI.0b013e3181829f62
20. Wei M. Q., Ellem K. A. O., Dunn P., West M. J., Bai C. X., Vogelstein B., Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. European Journal of Cancer 2007 43 3 490 496 2-s2.0-33846576538 10.1016/j.ejca.2006.10.005 (Pubitemid 46177582)
21. Park J., Jeon D., Yoon H., Kwon S., Kim S., Ahn S., Yoon J., Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma. Acta Odontologica Scandinavica 2012 70 3 241 245 2-s2.0-84859887762 10.3109/00016357.2011.640278
22. Igartua M., Pedraz J. L., Topical resiquimod: a promising adjuvant for vaccine development? Expert Review of Vaccines 2010 9 1 23 27 2-s2.0-74349122739 10.1586/erv.09.135
23. Celis E., Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Research 2007 67 17 7945 7947 2-s2.0-34548569047 10.1158/0008-5472.CAN-07-1652 (Pubitemid 47395122)
24. Jin B., Sun T., Yu X. H., Yang Y. X., Yeo A. E., The effects of TLR activation on T-cell development and differentiation. Clinical and Developmental Immunology 2012 2012 32 836485 10.1155/2012/836485
25. Kaisho T., Akira S., Regulation of dendritic cell function through toll-like receptors. Current Molecular Medicine 2003 3 4 373 385 2-s2.0-0038781697 10.2174/1566524033479726 (Pubitemid 36621794)
26. Meyer T., Stockfleth E., Clinical investigations of toll-like receptor agonists. Expert Opinion on Investigational Drugs 2008 17 7 1051 1065 2-s2.0-48249107883 10.1517/13543784.17.7.1051
27. Furrie E., Macfarlane S., Thomson G., Macfarlane G. T., Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005 115 4 565 574 2-s2.0-22744453319 10.1111/j.1365-2567.2005.02200.x (Pubitemid 41032444)
28. Kluwe J., Mencin A., Schwabe R. F., Toll-like receptors, wound healing, and carcinogenesis. Journal of Molecular Medicine 2009 87 2 125 138 2-s2.0-58549089483 10.1007/s00109-008-0426-z
29. Rajput S., Volk-Draper L. D., Ran S., TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Molecular Cancer Therapeutics 2013 12 8 1676 1687
30. Bohnhorst J., Rasmussen T., Moen S. H., Fløttum M., Knudsen L., Børset M., Espevik T., Sundan A., Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006 20 6 1138 1144 2-s2.0-33744459726 10.1038/sj.leu.2404225 (Pubitemid 43797309)
31. Bao H., Lu P., Li Y., Wang L., Li H., He D., Yang Y., Zhao Y., Yang L., Wang M., Yi Q., Cai Z., Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biology and Therapy 2011 11 1 58 67 2-s2.0-78751518366 10.4161/cbt.11.1.13878
32. O'Leary D. P., Bhatt L., Woolley J. F., Gough D. R., Wang J. H., Cotter T. G., Redmond H. P., TLR-4 signalling accelerates colon cancer cell adhesion via NF- B mediated transcriptional up-regulation of Nox-1. PLoS ONE 2012 7 e44176
33. Rhee S. H., Im E., Pothoulakis C., Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008 135 2 518 528 2-s2.0-48549106083 10.1053/j.gastro.2008.04.022
34. Zhao X., Ai M., Guo Y., Zhou X., Wang L., Li X., Yao C., Poly I: C-induced tumor cell apoptosis mediated by pattern-recognition receptors. Cancer Biotherapy and Radiopharmaceuticals 2012 27 530 534
35. Meyer T., Surber C., French L. E., Stockfleth E., Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opinion on Investigational Drugs 2013 22 149 159
36. Bourquin C., Hotz C., Noerenberg D., Voelkl A., Heidegger S., Roetzer L. C., Storch B., Sandholzer N., Wurzenberger C., Anz D., Endres S., Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Research 2011 71 15 5123 5133 2-s2.0-79960956913 10.1158/0008-5472.CAN-10-3903
37. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P., Boulamatsis D., Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. British Journal of Cancer 2002 87 1 21 27 2-s2.0-0036649794 10.1038/sj.bjc.6600347
38. Klier U., Maletzki C., Kreikemeyer B., Klar E., Linnebacher M., Combining bacterial-immunotherapy with therapeutic antibodies: a novel therapeutic concept. Vaccine 2012 30 17 2786 2794 2-s2.0-84858703373 10.1016/j.vaccine.2012. 01.071
39. Klier U., Maletzki C., Göttmann N., Kreikemeyer B., Linnebacher M., Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cellular Immunology 2011 269 2 120 127 2-s2.0-79957651432 10.1016/j.cellimm.2011.03.014
40. Geller M. A., Miller J. S., Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 2011 3 12 1445 1459 2-s2.0-81855173498 10.2217/imt.11.131
41. Geller M. A., Cooley S., Argenta P. A., Downs L. S., Carson L. F., Judson P. L., Ghebre R., Weigel B., Panoskaltsis-Mortari A., Curtsinger J., Miller J. S., Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunology, Immunotherapy 2010 59 12 1877 1884 2-s2.0-77957659880 10.1007/s00262-010-0914-1
42. Adams S., Toll-like receptor agonists in cancer therapy. Immunotherapy 2009 1 6 949 964 2-s2.0-77953469710 10.2217/imt.09.70
43. Ikeguchi M., Arai Y., Maeta Y., Ashida K., Katano K., Wakatsuki T., Topoisomerase i expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surgery Today 2011 41 9 1196 1199 2-s2.0-80052413958 10.1007/s00595-011-4546-7
44. Rehli M., Of mice and men: species variations of Toll-like receptor expression. Trends in Immunology 2002 23 8 375 378 2-s2.0-0036679732 10.1016/S1471-4906(02)02259-7 (Pubitemid 34804626)
45. Lu H., Wagner W. M., Gad E., Yang Y., Duan H., Amon L. M., Van Denend N., Larson E. R., Chang A., Tufvesson H., Disis M. L., Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. Journal of Immunology 2010 184 9 5360 5367 2-s2.0-77954514970 10.4049/jimmunol.0902997